PEPTONIC Medical AB: Peptonic Medical AB clarifies expected conclusion of its corporate reconstruction
Peptonic Medical AB (publ) ("Peptonic" or the "Company") clarifies the next steps in the reconstruction process and when the Company's corporate reconstruction is expected to conclude, following the approval of the reconstruction plan by the Uppsala District Court on 28 November 2025. In connection with the court's decision, it was also determined that the corporate reconstruction will terminate on the date the reconstruction plan becomes legally binding.
The decision to approve the reconstruction plan replaces the District Court's previous decision to extend the corporate reconstruction until 16 December 2025. Any appeals against the reconstruction plan must be submitted to the Court of Appeal no later than 19 December 2025. If no appeals are made, the reconstruction plan will take effect, thereafter, meaning that the corporate reconstruction will formally conclude.
For further information, please contact: Anna Linton, CEO, Peptonic Medical AB Email: anna.linton@peptonicmedical.se Phone: +46 70-244 92 07
About Peptonic Medical AB Peptonic Medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.